7 results on '"Udengaard, Hanne"'
Search Results
2. Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF:a multicentre, randomized, double-blinded placebo-controlled trial
- Author
-
Bülow, Nathalie Søderhamn, Skouby, Sven Olaf, Warzecha, Agnieszka Katarzyna, Udengaard, Hanne, Andersen, Claus Yding, Holt, Marianne Dreyer, Grøndahl, Marie Louise, Nyboe Andersen, Anders, Sopa, Negjyp, Mikkelsen, Anne Lis Englund, Pinborg, Anja, Macklon, Nicholas Stephen, Bülow, Nathalie Søderhamn, Skouby, Sven Olaf, Warzecha, Agnieszka Katarzyna, Udengaard, Hanne, Andersen, Claus Yding, Holt, Marianne Dreyer, Grøndahl, Marie Louise, Nyboe Andersen, Anders, Sopa, Negjyp, Mikkelsen, Anne Lis Englund, Pinborg, Anja, and Macklon, Nicholas Stephen
- Abstract
Study Question: Does letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF reduce the proportion of women with premature progesterone levels above 1.5 ng/ml at the time of triggering final oocyte maturation? Summary Answer: The proportion of women with premature progesterone above 1.5 ng/ml was not significantly affected by letrozole co-treatment. WHAT IS KNOWN ALREADY: IVF creates multiple follicles with supraphysiological levels of sex steroids interrupting the endocrine milieu and affects the window of implantation. Letrozole is an effective aromatase inhibitor, normalizing serum oestradiol, thereby ameliorating some of the detrimental effects of IVF treatment. STUDY DESIGN, SIZE, DURATION: A randomized, double-blinded placebo-controlled trial investigated letrozole intervention during stimulation for IVF with FSH. The trial was conducted at four fertility clinics at University Hospitals in Denmark from August 2016 to November 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: A cohort of 129 women with expected normal ovarian reserve (anti-Müllerian hormone 8-32 nmol/l) completed an IVF cycle with fresh embryo transfer and received co-treatment with either 5 mg/day letrozole (n = 67) or placebo (n = 62), along with the FSH. Progesterone, oestradiol, FSH, LH and androgens were analysed in repeated serum samples collected from the start of the stimulation to the mid-luteal phase. In addition, the effect of letrozole on reproductive outcomes, total FSH consumption and adverse events were assessed. MAIN RESULTS AND THE ROLE OF CHANCE: The proportion of women with premature progesterone >1.5 ng/ml was similar (6% vs 0% (OR 0.0, 95% CI [0.0; 1.6], P = 0.12) in the letrozole versus placebo groups, respectively), whereas the proportion of women with mid-luteal progesterone >30 ng/ml was significantly increased in the letrozole group: (59% vs 31% (OR 3.3, 95% CI [1.4; 7.1], P = 0.005)). Letrozole versus placebo decreased oestradiol levels on
- Published
- 2022
3. Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial
- Author
-
Bülow, Nathalie Søderhamn, primary, Skouby, Sven Olaf, additional, Warzecha, Agnieszka Katarzyna, additional, Udengaard, Hanne, additional, Andersen, Claus Yding, additional, Holt, Marianne Dreyer, additional, Grøndahl, Marie Louise, additional, Nyboe Andersen, Anders, additional, Sopa, Negjyp, additional, Mikkelsen, Anne Lis Englund, additional, Pinborg, Anja, additional, and Macklon, Nicholas Stephen, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Treatment with the anti-IgE monoclonal antibody omalizumab in women with asthma undergoing fertility treatment:a proof-of-concept study - The PRO-ART study protocol
- Author
-
Tidemandsen, Casper, Juul Gade, Elisabeth, Ulrik, Charlotte Suppli, Nielsen, Henriette Svarre, Oxlund-Mariegaard, Birgitte Sophie, Kristiansen, Karsten, Freiesleben, Nina La Cour, Nøhr, Bugge, Udengaard, Hanne, Backer, Vibeke, Tidemandsen, Casper, Juul Gade, Elisabeth, Ulrik, Charlotte Suppli, Nielsen, Henriette Svarre, Oxlund-Mariegaard, Birgitte Sophie, Kristiansen, Karsten, Freiesleben, Nina La Cour, Nøhr, Bugge, Udengaard, Hanne, and Backer, Vibeke
- Abstract
Introduction Asthma is associated with prolonged time to pregnancy and a higher need for fertility treatment. However, the mechanism underlying this association remains incompletely understood. Previous research points to asthma-driven systemic inflammation also affecting the reproductive organs and thereby fertility. The aim of this study was to determine if treatment with omalizumab prior to fertility treatment will increase pregnancy rate among women with asthma by decreasing the systemic asthma-related inflammation and, by that, to provide insight into the underlying mechanisms. Methods and analysis This is an ongoing prospective multicentre randomised controlled trial planned to enrol 180 women with asthma recruited from fertility clinics in Denmark. The patients are randomised 1:1 to either omalizumab or placebo. The primary endpoint is the difference in pregnancy rate confirmed with ultrasound at gestational week 7 of pregnancy. The secondary endpoints are change in sputum and blood eosinophil cell count, change in biomarkers, change in microbiota, together with rate of pregnancy loss, frequency of malformations, pre-eclampsia, preterm birth, birth weight, small for gestational age and perinatal death between groups. Ethics and dissemination The methods used in this study are of low risk, but if successful, our findings will have a large impact on a large group of patients as infertility and asthma are the most common chronic diseases among the young population. The study has been approved by the Ethics Committee-Danish national research ethics committee (H-18016605) and the Danish Medicines Agency (EudraCT no: 2018-001137-41) and the Danish Data Protection Agency (journal number: VD-2018486 and I-Suite number 6745). The test results will be published regardless of whether they are positive, negative or inconclusive. Publication in international peer-reviewed scientific journals is planned. Trial registration number NCT03727971.
- Published
- 2020
5. Treatment with the anti-IgE monoclonal antibody omalizumab in women with asthma undergoing fertility treatment: a proof-of-concept study—The PRO-ART study protocol
- Author
-
Tidemandsen, Casper, primary, Juul Gade, Elisabeth, additional, Ulrik, Charlotte Suppli, additional, Nielsen, Henriette Svarre, additional, Oxlund-Mariegaard, Birgitte Sophie, additional, Kristiansen, Karsten, additional, Freiesleben, Nina La Cour, additional, Nøhr, Bugge, additional, Udengaard, Hanne, additional, and Backer, Vibeke, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial.
- Author
-
Bülow, Nathalie Søderhamn, Skouby, Sven Olaf, Warzecha, Agnieszka Katarzyna, Udengaard, Hanne, Andersen, Claus Yding, Holt, Marianne Dreyer, Grøndahl, Marie Louise, Andersen, Anders Nyboe, Sopa, Negjyp, Mikkelsen, Anne Lis Englund, Pinborg, Anja, Macklon, Nicholas Stephen, and Nyboe Andersen, Anders
- Subjects
INDUCED ovulation ,FROZEN human embryos ,OVARIAN reserve ,HUMAN in vitro fertilization ,LETROZOLE ,FERTILIZATION in vitro ,LUTEAL phase ,RESEARCH ,PROGESTERONE ,FOLLICLE-stimulating hormone ,CLINICAL trials ,BIRTH rate ,ESTRADIOL ,ANDROGENS ,GONADOTROPIN ,RESEARCH funding - Abstract
Study Question: Does letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF reduce the proportion of women with premature progesterone levels above 1.5 ng/ml at the time of triggering final oocyte maturation?Summary Answer: The proportion of women with premature progesterone above 1.5 ng/ml was not significantly affected by letrozole co-treatment.What Is Known Already: IVF creates multiple follicles with supraphysiological levels of sex steroids interrupting the endocrine milieu and affects the window of implantation. Letrozole is an effective aromatase inhibitor, normalizing serum oestradiol, thereby ameliorating some of the detrimental effects of IVF treatment.Study Design, Size, Duration: A randomized, double-blinded placebo-controlled trial investigated letrozole intervention during stimulation for IVF with FSH. The trial was conducted at four fertility clinics at University Hospitals in Denmark from August 2016 to November 2018.Participants/materials, Setting, Methods: A cohort of 129 women with expected normal ovarian reserve (anti-Müllerian hormone 8-32 nmol/l) completed an IVF cycle with fresh embryo transfer and received co-treatment with either 5 mg/day letrozole (n = 67) or placebo (n = 62), along with the FSH. Progesterone, oestradiol, FSH, LH and androgens were analysed in repeated serum samples collected from the start of the stimulation to the mid-luteal phase. In addition, the effect of letrozole on reproductive outcomes, total FSH consumption and adverse events were assessed.Main Results and the Role Of Chance: The proportion of women with premature progesterone >1.5 ng/ml was similar (6% vs 0% (OR 0.0, 95% CI [0.0; 1.6], P = 0.12) in the letrozole versus placebo groups, respectively), whereas the proportion of women with mid-luteal progesterone >30 ng/ml was significantly increased in the letrozole group: (59% vs 31% (OR 3.3, 95% CI [1.4; 7.1], P = 0.005)). Letrozole versus placebo decreased oestradiol levels on the ovulation trigger day by 68% (95% CI [60%; 75%], P < 0.0001). Other hormonal profiles, measured as AUC, showed the following results. The increase in LH in the letrozole group versus placebo group was 38% (95% CI [21%; 58%], P < 0.0001) and 34% (95% CI [11%; 61%], P = 0.006) in the follicular and luteal phases, respectively. In the letrozole group versus placebo group, testosterone increased by 79% (95% CI [55%; 105%], P < 0.0001) and 49% (95% CI [30%; 72%], P < 0.0001) in the follicular and luteal phases, respectively. In the letrozole group versus placebo group, the increase in androstenedione was by 85% (95% CI [59%; 114%], P < 0.0001) and 69% (95% CI [48%; 94%], P < 0.0001) in the follicular and luteal phases, respectively. The ongoing pregnancy rate was similar between the letrozole and placebo groups (31% vs 39% (risk-difference of 8%, 95% CI [-25%; 11%], P = 0.55)). No serious adverse reactions were recorded in either group. The total duration of exogenous FSH stimulation was 1 day shorter in the intervention group, significantly reducing total FSH consumption (mean difference -100 IU, 95% CI [-192; -21], P = 0.03).Limitations, Reasons For Caution: Late follicular progesterone samples were collected on the day before and day of ovulation triggering for patient logistic considerations, and the recently emerged knowledge about diurnal variation of progesterone was not taken into account. The study was powered to detect hormonal variations but not differences in pregnancy outcomes.Wider Implications Of the Findings: Although the use of letrozole has no effect on the primary outcome, the number of women with a premature increase in progesterone on the day of ovulation triggering, the increased progesterone in the mid-luteal phase due to letrozole may contribute to optimizing the luteal phase endocrinology. The effect of letrozole on increasing androgens and reducing FSH consumption may be used in poor responders. However, the effect of letrozole on implantation and ongoing pregnancy rates should be evaluated in a meta-analysis or larger randomized controlled trial (RCT).Study Funding/competing Interest(s): Funding was received from EU Interreg for ReproUnion and Ferring Pharmaceuticals, and Roche Diagnostics contributed with assays. N.S.M. and A.P. have received grants from Ferring, Merck Serono, Anecova and Gedeon Richter, and/or personal fees from IBSA, Vivoplex, ArtPred and SPD, outside the submitted work. The remaining authors have no competing interests.Trial Registration Numbers: NCT02939898 and NCT02946684.Trial Registration Date: 15 August 2016.Date Of First Patient’s Enrolment: 22 August 2016. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Non-invasive prenatal paternity testing using the Precision ID Identity Panel
- Author
-
Christiansen, Sofie Lindgren, Jakobsen, Britt, Børsting, Claus, Udengaard, Hanne, Buchard, Anders, Kampmann, Marie-Louise, Grøndahl, Marie Louise, Morling, Niels, Christiansen, Sofie Lindgren, Jakobsen, Britt, Børsting, Claus, Udengaard, Hanne, Buchard, Anders, Kampmann, Marie-Louise, Grøndahl, Marie Louise, and Morling, Niels
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.